Results 111 to 120 of about 1,610 (149)
Some of the next articles are maybe not open access.
Rehabilitation of patients with vulvovaginal atrophy
Journal of Medical RehabilitationBackground. Genitourinary syndrome of menopause (GSM) is characterized by a number of pathological changes, in particular urological disorders, vulvovaginal atrophy (VVA) and sexual dysfunction. They are commonly accompanied by decreased quality of life (QoL) and often require medical intervention. At the same time, the steps taken to effectively solve
P. L. Khazan +4 more
openaire +1 more source
Laser Treatment for Vulvovaginal Atrophy
2019Laser therapy has a therapeutic role for different medical conditions and most recently has gained interest as a non-hormonal treatment for vulvovaginal atrophy or genitourinary syndrome of menopause (GSM). Both microablative fractional CO2 laser and the second-generation non-ablative vaginal Er:YAG laser (VEL) can alleviate the symptoms of dryness and
openaire +1 more source
[Sulphurous vaginal douching and vulvovaginal atrophy].
La Clinica terapeutica, 2018During climacteric the reduction or interruption of estrogenic stimulus determines a gradual atrophy of the tissues of the urogenital tract.Vulvovaginal atrophy can be cause of dryness, itch, burning, and dyspareunia. Vulvovaginal atrophy is associated also with depression.
M, Costantino +4 more
openaire +1 more source
Fractional CO2 Laser for Vulvovaginal Atrophy.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2018To evaluate the short term efficacy and safety of Fractional CO2 laser for the treatment of vulvovaginal atrophy.From March 2015 to October 2015, 112 menopausal women were recruited. All women with VVA were treated by using Fractional CO2 laser; power 30 watts, 1-3 stacks with 360° vaginal probe for 3 consecutive times, 4 weeks apart.
Orawan, Lekskulchai +2 more
openaire +1 more source
Current and Emerging Treatment Options for Vulvovaginal Atrophy
2014Vulvovaginal atrophy in postmenopausal women is common and manifests in vaginal dryness, irritation, itching, dysuria, and dyspareunia. Treatment used to be limited to estrogen-containing regimens which pose safety concerns. Today, however, practitioners are becoming better equipped to offer a wider range of treatment options due to increased ...
Jill M. Krapf +3 more
openaire +1 more source
Vulvovaginal atrophy: current and future therapies (CME).
The journal of sexual medicine, 2010Vulvovaginal atrophy results from estrogen deficiency and affects a large number of postmenopausal women. Symptoms include vaginal dryness, itching, irritation, and dyspareunia.The purpose of this review is to evaluate the efficacy, safety and acceptability of current treatment methods for vulvovaginal atrophy, as well as highlight evolving new ...
Comfort, Ibe, James A, Simon
openaire +1 more source
Integrative oncology: Addressing the global challenges of cancer prevention and treatment
Ca-A Cancer Journal for Clinicians, 2022Jun J Mao,, Msce +2 more
exaly